FIGURE 5.

IL‐22 treatment repressed the transforming growth factor (TGF)‐β pathway and the production of collagen in vitro. Samples were collected at 24, 48, and 72 h after treatment cells with 10 ng/ml human interleukin (IL)‐22 and 5 ng/ml TGF‐β1 for mRNA or protein analysis (n = 3). (A–B) In both A549 and mouse primary AT2 cells, the expressions of TGF‐βR2, α‐smooth muscle actin (α‐SMA), Collagen‐I, and E‐cad after treatment with TGF‐β1 and/or IL‐22 by WB. (C–D) In both HELF and human primary fibroblasts (FB), the expressions of TGF‐βR2, α‐SMA, Collagen‐I and Vimentin after treatment with TGF‐β1 and/or IL‐22 by WB. (E–L) The mRNA expressions of TGF‐βR2, α‐SMA, Collagen‐I and E‐cad after treatment with TGF‐β1 and/or IL‐22 by real‐time PCR in both type II AECs (A549 cell line and mouse primary AT2). (M–T) The mRNA expressions of TGF‐βR2, α‐SMA, Collagen‐I, and Vimentin after treatment with TGF‐β1 and/or IL‐22 in both fibroblasts (HELF cell line and human primary FB) by real‐time PCR